Recent Updates — CRLBF

Cresco Labs reported third-quarter 2026 net loss of $14.5 million and revenue of $172.8 million, a 4.8% increase year-over-year driven by dispensary acquisitions in Pennsylvania and retail growth in Ohio. Gross profit was $79.5 million with an adjusted EBITDA of $34.9 million. The company generated $35.9 million in operating cash flow for the nine-month period. Separately, shareholders approved a proposed redomicile to Delaware and the creation of a new parent TopCo to simplify capital structure ahead of U.S. market access. Cresco Labs is a licensed cultivator, manufacturer, and distributor of cannabis products operating Sunnyside dispensaries across multiple U.S. states.

Shareholders approved three special resolutions at the October 30, 2026 meeting by at least 94% of votes cast. The measures include creating a new parent company (TopCo) to facilitate an exchange of securities, a potential redomicile from British Columbia to Delaware, and extending the listing sunset date for multiple voting shares. Seven directors were also elected. Cresco Labs operates in the cannabis industry, focusing on cultivation, production, branded product distribution, and retail dispensary operations.

Cresco Labs Inc. reported second quarter 2026 financial results for the period ended June 30, 2026. Net revenue increased 5.9% to $173.3 million, driven by dispensary acquisitions in Pennsylvania and retail growth in Ohio. Gross profit rose 4.4% to $86.9 million, while SG&A expenses increased 27.2% to $73.6 million due to higher salaries and professional fees. The company reported a net income of $15.4 million, a significant turnaround from the $13.9 million loss in the prior year period, primarily attributable to a $19.0 million income tax benefit resulting from the removal of IRC Section 280E restrictions for state-licensed medical cannabis operations effective April 22, 2026. Adjusted EBITDA was $40 million. Additionally, Chief Financial Officer Sharon Schuler stepped down, with Mark Stortz serving as interim CFO. Cresco Labs Inc. operates in the cannabis industry, cultivating and distributing branded cannabis products through its Sunnyside retail dispensaries.